Post-Thrombectomy Care: Evidence-Based Management After Endovascular Therapy

Despite high recanalization rates with modern thrombectomy techniques, approximately half of patients do not achieve functional independence. Optimizing post-procedural care—including blood pressure management, monitoring for complications, and timing of secondary prevention—is critical to maximizing outcomes after successful reperfusion.

1. Blood Pressure Management

Post-thrombectomy blood pressure management has been one of the most debated topics in neurocritical care. While observational data suggested lower BP targets might reduce hemorrhagic transformation, multiple RCTs have now shown that intensive BP lowering may cause harm.

BP-TARGET Trial (2021)

The first RCT in this space randomized 324 patients with successful EVT to intensive (SBP 100–129 mmHg) vs. standard (130–185 mmHg) BP control for 24 hours.

• Primary outcome: No difference in ICH at 24–36h (parenchymal hematoma type 2: 12% vs. 9%)
• Functional outcome: No significant difference in mRS at 90 days
• Achieved BP: 128 mmHg vs. 138 mmHg (modest 10 mmHg separation)

Conclusion: Intensive BP lowering was safe but showed no benefit in reducing hemorrhage.

ENCHANTED2/MT Trial (2022)

This large Chinese trial (n=821) tested more aggressive BP targets: SBP <120 mmHg vs. 140–180 mmHg, maintained for 72 hours. The trial was stopped early for harm.

• Primary outcome: More intensive group had worse functional outcomes (OR 1.37 for poor outcome)
• Early neurological deterioration: Higher in intensive group (OR 1.53)
• sICH: No significant difference between groups
• Major disability at 90 days: OR 2.07 favoring less intensive treatment

Critical Pearl: SBP <120 mmHg should be avoided — it worsens outcomes without reducing ICH risk.

BEST-II Trial (2023)

A phase 2 futility trial comparing three BP targets: <140, <160, and ≤180 mmHg in 120 patients.

• 36-hour infarct volume: Smallest in <140 mmHg group (32.4 mL vs. 50.7 mL vs. 46.4 mL)
• 90-day mRS: Trend toward harm with lower targets (not statistically significant)
• Conclusion: Lower BP targets unlikely to improve outcomes; may trend toward harm

OPTIMAL-BP Trial (2023)

Korean trial (n=306) comparing SBP <140 mmHg vs. 140–180 mmHg. Also stopped early after ENCHANTED2/MT results.

• Primary outcome: mRS 0–2 at 90 days lower in intensive group (49.7% vs. 58.4%)
• Achieved BP: 129 mmHg vs. 138 mmHg
• Subgroup finding: Patients requiring multiple thrombectomy passes had significantly worse outcomes with intensive BP control

Clinical Practice: Current evidence supports maintaining SBP <180 mmHg (guideline-recommended). Avoid targets <120 mmHg. A range of 140–180 mmHg appears safe. Consider individualizing based on reperfusion status—patients with incomplete recanalization may tolerate higher BP.

2. Hemorrhagic Transformation

Hemorrhagic transformation (HT) remains a major concern after thrombectomy, occurring in 15–40% of patients depending on classification. The Heidelberg Bleeding Classification distinguishes between hemorrhagic infarction (HI) and parenchymal hematoma (PH), with only PH consistently associated with worse outcomes.

Risk Factors for HT After EVT

• Patient factors: Atrial fibrillation, hyperglycemia, older age, higher baseline NIHSS
• Imaging factors: Large infarct core, poor collaterals, hyperdense artery sign
• Procedural factors: Incomplete recanalization, multiple thrombectomy passes, longer procedure time
• Protective factors: Complete recanalization (TICI 3), hyperlipidemia (paradoxically)

Monitoring Protocol

• Neuro checks: q15 min × 2h, q30 min × 6h, then q1h until 24h post-procedure
• Follow-up imaging: Non-contrast CT at 24 ± 12 hours (routine) or immediately if neurological deterioration
• Blood pressure monitoring: Continuous or q15 min initially; avoid wide variability

Classification of HT (ECASS Criteria)

• HI-1: Small petechiae along margins of infarct
• HI-2: More confluent petechiae within infarct, no mass effect
• PH-1: Hematoma ≤30% of infarct with mild mass effect
• PH-2: Hematoma >30% of infarct with significant mass effect — associated with clinical deterioration

Key Insight: HI is often an incidental finding and may not require intervention. PH, particularly PH-2, is the clinically relevant form associated with worse outcomes and may require reversal of anticoagulation, BP management, and neurosurgical consultation.

3. Antiplatelet Therapy

Without Prior IV tPA

In patients who underwent direct thrombectomy without IV thrombolysis, antiplatelet therapy can be initiated within 24 hours. Options include:

• Aspirin 81 mg daily
• DAPT (aspirin + clopidogrel) for 21 days in non-cardioembolic, minor strokes based on CHANCE trial

After IV tPA

Standard practice remains withholding antiplatelets for 24 hours post-tPA, with follow-up imaging to exclude significant hemorrhage before initiation.

If Carotid or Intracranial Stent Used

DAPT is typically recommended if stenting was performed. Duration varies (usually 1–3 months), followed by single antiplatelet therapy.

4. Access Site Management

Femoral artery access is standard for most thrombectomy procedures. Post-procedural care includes:

• Bed rest: Typically 2–6 hours depending on closure device used
• Groin checks: Monitor for hematoma, pseudoaneurysm, or retroperitoneal hemorrhage
• Warning signs: Flank pain, hemodynamic instability, dropping hemoglobin
• Closure devices: Angioseal, Mynx, or manual compression

5. Additional Considerations

ICU vs. Stroke Unit Disposition

Most centers admit post-thrombectomy patients to ICU or step-down unit for at least 24 hours for close monitoring. Evidence on optimal disposition is limited, but high-risk features (incomplete recanalization, large core, procedural complications) warrant ICU-level care.

Contrast-Related Considerations

• Hydration: IV fluids post-procedure, especially in patients with renal impairment
• Renal function: Check creatinine at 24–48 hours if baseline impairment or high contrast volume
• Contrast staining: Can mimic hemorrhage on CT; typically resolves within 24–48 hours

Early Mobilization

Based on AVERT trial principles and access site considerations:

• Delay mobilization at least 12–24 hours post-procedure
• Consider longer bed rest if femoral closure issues or neurological instability
• Early PT/OT evaluation once stable

Conclusion

Post-thrombectomy care has evolved significantly with new RCT evidence. Key takeaways include avoiding aggressive BP lowering (<120 mmHg causes harm), recognizing that early anticoagulation for AF is safe even after EVT, and maintaining vigilance for hemorrhagic transformation with routine follow-up imaging. Individualized management based on reperfusion status, infarct size, and comorbidities remains essential.